HC Wainwright Reiterates Buy Rating for GH Research (NASDAQ:GHRS)

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $40.00 target price on the stock.

Separately, Canaccord Genuity Group cut their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.

GH Research Trading Down 4.6 %

Shares of NASDAQ GHRS opened at $8.57 on Friday. GH Research has a 12-month low of $5.50 and a 12-month high of $14.99. The firm has a market capitalization of $445.88 million, a price-to-earnings ratio of -10.85 and a beta of 0.84. The firm has a 50 day moving average of $8.44 and a 200 day moving average of $9.20.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its position in GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the quarter. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).